The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...

Some Canadians will be able to buy brand-name GLP-1 drug Ozempic at a reduced price, Danish drugmaker Novo Nordisk said in a statement Tuesday. The move comes as two generic versions of Ozempic and ...

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx. The platform, which launched in February, is key to his administration's ...

President Trump announced the addition of 600 medicines to his online drugstore as he appeals to Americans concerned about high drug prices and affordability. By Rebecca Robbins President Trump said ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.